3 Top Growth Plays That Could Smash The FTSE 100: ARM Holdings plc, GlaxoSmithKline plc & Diageo plc

Though the FTSE 100 (INDEXFTSE:UKX) could go much higher, ARM Holdings plc (LON:ARM), GlaxoSmithKline plc (LON:GSK) & Diageo plc (LON:DGE) could beat it.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE100

With the S&P 500 hitting record highs, 2014 has been something of a disappointment for the FTSE 100. Indeed, the index is up just 1% since the turn of the year, but does seem to have huge potential over the medium term. That’s because it trades on a price to earnings (P/E) ratio of just 13.8 and has a yield of around 3.5% — both of which indicate that the index could push northwards.

However, here are three shares that despite the FTSE 100’s potential, could still outperform the UK’s main index.

ARM

Although shares in ARM (LSE: ARM) have fallen by 12% during the course of 2014, the intellectual property business could beat the FTSE 100 going forward. That’s because it offers investors a vast amount of growth potential, with the company’s earnings per share (EPS) expected to increase by an impressive 23% in 2015. Furthermore, with shares in ARM having fallen, they now represent much better value for money. Indeed, although ARM’s price to earnings (P/E) ratio remains high at 41.5, its price to earnings growth (PEG) ratio of just 1.5 means that it could outperform the FTSE 100 over the medium term.

GlaxoSmithKline

As with ARM, 2014 has been a tough year for GlaxoSmithKline (LSE: GSK). Its shares have dropped by 9% and the company continues to suffer from weak sentiment due to bribery allegations. However, GlaxoSmithKline also has a highly diversified and capable drugs pipeline that has the potential to deliver brisk earnings growth in future years. Certainly, all drug pipelines come with a large dollop of uncertainty, but GlaxoSmithKline appears to have a well-balanced pipeline that should benefit from a renewed focus by the company after the sale of its consumer brands. In the meantime, a yield of 5.6% should help to push investors’ total return above that of the FTSE 100.

Diageo

Diageo (LSE: DGE) is also down in 2014, with the alcoholic beverages company seeing its share price fall by 12% year-to-date. However, demand for premium alcoholic drinks should remain robust in the long run – even if the world economy does fall back into negative growth territory. Moreover, Diageo’s strong stable of brands should ensure that demand for its products remains buoyant in developed nations, while emerging markets such as China and India present a huge opportunity for the company to increase its sales and profitability. As a result, it could have a much brighter future and has the scope to beat the main index moving forward.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended shares in GlaxoSmithKline and ARM Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how I’d aim for a ton of passive income from £20k in an ISA

To get the best passive income from an ISA, I think we need to balance risk with the potential rewards.…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

2 FTSE 100 stocks I’d buy as the blue-chip index hits record highs

This Fool takes a look at a pair of quality FTSE 100 stocks that appear well-positioned for future gains, despite…

Read more »

Satellite on planet background
Small-Cap Shares

Here’s why AIM stock Filtronic is up 44% today

The share price of AIM stock Filtronic has surged on the back of some big news in relation to its…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

At a record high, there can still be bargain FTSE 100 shares to buy!

The FTSE 100 closed at a new all-time high this week. Our writer explains why there might still be bargain…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

After profits plunge 28%, should investors consider buying Lloyds shares?

Lloyds has seen its shares wobble following the release of its latest results. But is this a chance for investors…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

Something’s changed in a good way for Reckitt in Q1, and the share price may be about to take off

With the Reckitt share price near 4,475p, is this a no-brainer stock? This long-time Fool takes a closer look at…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

This new boost in assets might just get the abrdn share price moving again

The abrdn share price has lost half its value in the past five years. But with investor confidence returning, are…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

As revenues rise 8%, is the Croda International share price set to bounce back?

The latest update from Croda International indicates that sales are starting to recover from the end of 2023, so is…

Read more »